Pricing Log in Create free account
Friday 6 November 2026 Export ORKA’s income statement to Excel — free account

Oruka Therapeutics, Inc.

ORKA Healthcare Biotechnology

EPS
−19.6%
Free cash flow
−43.0%

Quarter to June 2026, against a year earlier

102.68 6.66 +6.94%
Market cap
$6.4B
P/E
0.0×
Fwd P/E
—
Dividend yield
0.00%
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Valuation Filings

Oruka Therapeutics, Inc. (ORKA) valuation and DCF model

What the price implies · reverse DCF

Oruka Therapeutics, Inc. is not valued here: free cash flow is negative and there is no revenue to read the price through.

Valuation against its own history

Today’s multiple against its 5- and 10-year averages and the industry median (Biotechnology).

Multiple Current 5Y avg 10Y avg vs 10Y avg Industry median vs industry 10Y range
P/B 5.47× 5.47× 5.47× 0% above 2.05× 167% above

ORKA trades at 5.47× P/B, against a 10-year average of 5.47× (range 5.47×–5.47×). Re-rating to the average implies $102.68 per share.

Every growth rate on this page is the business’s — its cash flow, FFO or dividend — never its share price’s. A discounted-cash-flow model is only as good as its assumptions. Figures from the 10-K and 10-Q filings. Not investment advice.